Ozempic Gastroparesis Settlement: Claim Valuation Factors Overview

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From Public Health Education to Pharmaceutical Risk Awareness

The legacy of general health and science information has long served as a foundation for public understanding of disease prevention and treatment. This heritage, rooted in broad educational outreach, has historically focused on communicable conditions such as the Ebola virus epidemic in West Africa, where situational mapping and case reporting were critical for awareness. Over time, this informational framework has expanded to encompass chronic disease management and pharmaceutical interventions, reflecting evolving public health priorities. As the scope of health communication broadens, attention has increasingly turned to the long-term effects of widely prescribed medications. This shift naturally leads to a focus on occupational exposure concerns, particularly for professionals who regularly encounter patients using these therapies. In the context of mass production and clinical practice, understanding the implications of drug exposure—such as that associated with Ozempic—becomes essential. The transition from general health literacy to specific exposure risk assessment represents a logical progression, where the same principles of information dissemination now apply to evaluating potential adverse outcomes in both patient and occupational settings.

Bridging to Ozempic and Gastroparesis

Building on the foundation of health information dissemination, this section transitions to a focused examination of Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Its use has been associated with a range of gastrointestinal adverse effects, including gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction. This narrative provides an evidence-grounded overview of factors relevant to potential settlement claims linking Ozempic to gastroparesis, drawing on clinical trial data, adverse-event reports, and mechanistic considerations.

Clinical Trial Evidence and Adverse Event Data

Clinical trial data from the Ozempic prescribing information indicate that gastrointestinal adverse reactions occur significantly more frequently among patients receiving Ozempic compared to placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients: 3.1% for 0.5 mg and 3.8% for 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% of patients on 1 mg and 34.0% of those on 2 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal reactions reported at frequencies below 5% include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Post-marketing surveillance data from the FDA Adverse Event Reporting System (FAERS) further highlight the association between Ozempic and impaired gastric emptying. Among the most frequently reported adverse events for Ozempic, "impaired gastric emptying" appears with 2,693 reports, alongside nausea (8,652 reports), vomiting (5,578 reports), diarrhea (5,274 reports), and constipation (3,859 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). These data suggest that gastroparesis is a recognized adverse event in the real-world setting, though FAERS reports are subject to limitations such as underreporting and lack of a control group.

Mechanistic Pathway and Risk Factors for Settlement Claims

The mechanistic pathway linking GLP-1 receptor agonists like Ozempic to gastroparesis involves the drug's effect on gastric motility. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and activation of these receptors slows gastric emptying, which is part of the drug's intended mechanism for glycemic control. However, excessive or prolonged slowing can lead to symptomatic gastroparesis, characterized by early satiety, postprandial fullness, nausea, vomiting, and abdominal pain. The clinical presentation of gastroparesis is diagnosed through gastric emptying scintigraphy or breath tests, and symptoms can overlap with other gastrointestinal disorders. The temporal relationship between Ozempic initiation and onset of gastroparesis symptoms is a critical factor in establishing causation for settlement claims. Risk anchors for settlement considerations include the adequacy of warnings provided by the manufacturer. The Ozempic prescribing information lists gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a separate warning. The label notes that gastrointestinal adverse reactions are common and may lead to discontinuation, but the specific term "gastroparesis" is not used in the adverse reactions section. This gap in explicit warning may be relevant to claims that patients and healthcare providers were not adequately informed of the risk of delayed gastric emptying. Settlement-related considerations also involve the timeline between exposure and documented harm. For affected patients, the onset of gastroparesis symptoms often occurs during dose escalation or after several months of treatment, and diagnosis may be delayed due to nonspecific symptoms. Documentation of the temporal relationship, including medical records showing Ozempic use and subsequent gastroparesis diagnosis, is essential for claim valuation. In summary, evidence from clinical trials and FAERS data supports an association between Ozempic and gastroparesis, with mechanistic plausibility through GLP-1 receptor-mediated slowing of gastric emptying. Settlement valuation factors include the frequency and severity of gastrointestinal adverse reactions, the adequacy of product warnings, and the documented timeline of exposure and harm. Patients pursuing claims should gather medical records confirming gastroparesis diagnosis, Ozempic prescription history, and any evidence of inadequate warning or failure to monitor for gastrointestinal symptoms.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Ozempic and gastroparesis?

Clinical trials and post-marketing data show that Ozempic (semaglutide) significantly increases gastrointestinal adverse reactions, including delayed gastric emptying consistent with gastroparesis. In FAERS, impaired gastric emptying is among the most reported events, with 2,693 reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). Mechanistically, GLP-1 receptor activation slows gastric motility, which can become excessive and symptomatic.

What factors are considered in valuing an Ozempic gastroparesis settlement claim?

Key factors include the frequency and severity of gastrointestinal adverse reactions, the adequacy of product warnings (the label does not explicitly mention gastroparesis), the documented timeline of Ozempic exposure and gastroparesis diagnosis, and evidence of inadequate monitoring or failure to warn. Medical records confirming diagnosis and prescription history are essential.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.